Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Luveltamab tazevibulin - Sutro Biopharma

Next Previous
Drug Profile

Luveltamab tazevibulin - Sutro Biopharma

Alternative Names: anti-FolRa ADC STRO-002; anti-FolRalpha ADC STRO-002; FolR-alpha-ADC-Sutro-Biopharma; Luvelta; STRO-002

Latest Information Update: 29 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sutro Biopharma
  • Developer Gynecologic Oncology Group; Sutro Biopharma; Tasly Biopharmaceuticals
  • Class Amides; Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Indoles
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Ovarian cancer
  • Phase I/II Solid tumours
  • Phase I Endometrial cancer; Fallopian tube cancer; Peritoneal cancer
  • Clinical Phase Unknown Acute myeloid leukaemia
  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 25 Mar 2024 Sutro Biopharma plans the phase II/III REFRaME-P1 trial in Acute myeloid leukemia (In children) in the second half of 2024
  • 14 Dec 2023 Luveltamab tazevibulin receives rare pediatric disease status for Acute myeloid leukemia in USA before December 2023
  • 09 Dec 2023 Efficacy and adverse events data from a compassionate use program in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top